What is Kura Oncology's EV / sales?

Kura Oncology (KURA) reported EV / sales of 9.8× in Q1 2026.

How has Kura Oncology's EV / sales changed year-over-year?

Kura Oncology's EV / sales increased by 6.8% year-over-year, from 9.2× to 9.8×.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

Kura Oncology KURA EV / sales

EV / sales at other companies

Johnson & JohnsonJNJ

6.5×+1.8×

AmgenAMGN

6.6×+0.1×

ExelixisEXEL

4.7×+0.3×

Syndax PharmaceuticalsSNDX

10.5×-17.9×

AbbVieABBV

7.5×+1.0×

Nuvation BioNUVB

9.9×-41.1×

Other financials

Income statement

See full

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

See full

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

See full

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

See full

Market cap$942.78M+81.6%

Enterprise value$927.97M+90.7%

P/S13.2×+3.6×

Profitability

See full

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

See full

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Calculated from Kura Oncology’s reported figures.

enterprise value/total revenue=9.8×

Based on the most recent quarter.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kura Oncology's EV / sales?: Kura Oncology (KURA) reported EV / sales of 9.8× in Q1 2026.
How has Kura Oncology's EV / sales changed year-over-year?: Kura Oncology's EV / sales increased by 6.8% year-over-year, from 9.2× to 9.8×.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.